Business e via Italy - Menarini Group, based in Florence, Italy, will acquire Stemline. It will give them a toehold in the United States, but the company also plans to continue to advance the development of its CD123-targeted therapy, Elzonris, the first ever-approved treatment for blastic plasmacytoid dendritic cell neoplasm. BPDCN is an aggressive, orphan blood disorder with historically poor outcomes. Stemline said that BPDCN can often present symptoms that can be mistaken for blood cancers, such as acute myeloid leukemia and non-Hodgkin’s lymphoma. #finance #business #madeinitaly #italy #investment #management #retail #merger #banking #setup #italian #fashion #distribution #food #automotive #industry #fashion #fashionweek #businessdevelopment #sales #internationalisation #realestate #assetmanagement #commercial #privateequity #realestate #assetmanagement #wealthmanagement
Comments